
Loading, please wait...

Loading, please wait...

Norway has demonstrated exceptional progress in its national response to HIV, effectively meeting international benchmarks. According to a recent study using linked registry data, the HIV continuum of care in the country shows remarkably high rates of linkage and treatment. These findings are crucial for medical professionals worldwide, especially as the global community strives to eliminate HIV as a public health threat by 2030.
Researchers analyzed data from 5,847 people living with HIV (PLHIV) diagnosed through 2023. The results indicate that clinicians linked 99.6% of these individuals to specialist care. Furthermore, 96.4% of the cohort received antiretroviral therapy (ART). Among the 4,926 PLHIV still residing in Norway in 2023, 96.7% maintained retention in care. Additionally, 95.3% of the group had received ART within the prior 24 months, highlighting a consistent and robust follow-up system.
The study also examined mortality rates to assess the long-term efficacy of these interventions. Specifically, the all-cause mortality rate stood at 4.7 per 1,000 person-years. In contrast, HIV/AIDS-specific mortality was 1.0 per 1,000 person-years among those without a concurrent AIDS diagnosis who used ART. Consequently, these figures suggest that early diagnosis and adherence to ART remain the cornerstones of survival. Moreover, the use of linked administrative and health registries provides a viable alternative for monitoring outcomes when a dedicated national clinical registry is absent.
Overall, Norway has achieved high levels of engagement in specialist HIV care. These results provide clear evidence of progress toward global clinical targets. Thus, the Norwegian model serves as a benchmark for utilizing comprehensive data systems to improve patient outcomes and guide public health strategies.
The HIV continuum of care is a public health model that tracks the stages of HIV care, including diagnosis, linkage to care, starting ART, and achieving viral suppression.
Norway used linked data from various national health and administrative registries, covering the period from 2008 to 2023, to track outcomes like ART dispensation and retention.
PLHIV on ART without a concurrent AIDS diagnosis at the time of study had the lowest HIV-specific mortality rate, recorded at 1.0 per 1,000 person-years.
Disclaimer: This content is for informational and educational purposes only and does not constitute medical advice or a professional opinion. Readers should consult with a qualified healthcare professional for specific medical concerns. Refer to the latest local and national guidelines for clinical practice.
References

Read summarized clinical updates, watch expert medical content, and earn CME certifications right from your smartphone.


Norway's registry-based study shows 96% ART uptake and low HIV-specific mortality among diagnosed PLHIV, meeting global elimination targets....
6 months ago

A breakthrough study evaluated H5N1 transmission efficiency across mammalian isolates. Researchers discovered that human-derived D1.1 harboring the PB2 D701N mutation spread efficiently in ferrets, unlike strains carrying PB2 E627K. This finding highlights critical genetic markers for zoonotic surveillance.
Today

A comparative cohort study evaluates vNOTES vs TLH hysterectomy for benign conditions, demonstrating shorter operative duration, faster return to daily activities, and equivalent female sexual function scores without increased dyspareunia.
Today

Review how tailored exercise programs benefit frail older patients with heart failure. Explore pathophysiological mechanisms, individualized training prescriptions, and strategies to overcome adherence barriers in clinical practice.
Yesterday

This comparative study evaluates posterior labral tears with and without glenohumeral instability, highlighting distinct demographic patterns, MRI underestimation in stable shoulders, and successful arthroscopic repair outcomes.
Yesterday

A clinical study demonstrates that early intervention with tocilizumab, either as monotherapy or bridged with corticosteroids, achieves significant proptosis reduction and resolves active inflammation in treatment-naive thyroid eye disease.
Today